Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - OPIANT PHARMACEUTICALS, INC. | v362307_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________
FORM 8-K
___________
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 3, 2013
LIGHTLAKE THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)
| Nevada | 333-139915 | N/A | ||
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employee Identification No.) |
86 Gloucester Place, Ground Floor Suite, London, England W1U 6HP
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: 44 (0) 203 617 8739
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 7.01 | Regulation FD. |
On December 3, 2013, Lightlake Therapeutics Inc., a Nevada corporation, (the “Company”) issued a press release entitled “Initial Data from Lightlake Therapeutics Joint Clinical Trial with NIDA Shows Nasal Delivery of Naloxone for Opioid Overdose as a Promising Treatment.” The press release discloses the initial data from the study regarding the Company’s intranasal delivery of naloxone. A copy of the press release is furnished herewith as Exhibit 99.1.
The information in this Item 7.01 of this Form 8-K is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Form 8-K also shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except to the extent that the Company specifically incorporates it by reference.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
| Exhibit No. | Description | |
| 99.1 | Lightlake Press Release – “Initial Data from Lightlake Therapeutics Joint Clinical Trial with NIDA Shows Nasal Delivery of Naloxone for Opioid Overdose as a Promising Treatment” dated December 3, 2013 (furnished herewith). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Lightlake Therapeutics Inc. | |||
| By: | /s/ Dr. Roger Crystal | ||
| Name: Dr. Roger Crystal | |||
| Title: President and Chief Executive Officer | |||
| Dated: December 6, 2013 | |||